Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 1;18(2):453-459.
doi: 10.5664/jcsm.9612.

Behaviorally and environmentally induced non-24-hour sleep-wake rhythm disorder in sighted patients

Affiliations

Behaviorally and environmentally induced non-24-hour sleep-wake rhythm disorder in sighted patients

Jonathan S Emens et al. J Clin Sleep Med. .

Abstract

Study objectives: To determine whether there was evidence of circadian or sleep-regulatory dysfunction in sighted individuals with non-24-hour sleep-wake rhythm disorder.

Methods: Three sighted individuals with signs and/or symptoms of non-24-hour sleep-wake rhythm disorder were studied. Thirty-five- to 332-day laboratory and home-based assessments of sleep-wake and circadian timing, endogenous circadian period, photic input to the circadian pacemaker, and/or circadian and sleep-wake-dependent regulation of sleep were conducted.

Results: No evidence of circadian dysfunction was found in these individuals. Instead, sleep-wake timing appeared to dissociate from the circadian timing system, and/or self-selected sleep-wake and associated light/dark timing shifted the circadian pacemaker later, rather than the circadian pacemaker determining sleep-wake timing.

Conclusions: These findings suggest that the etiology of this disorder may be light- and/or behaviorally induced in some sighted people, which has implications for the successful treatment of this disorder.

Citation: Emens JS, St Hilaire MA, Klerman EB, et al. Behaviorally and environmentally induced non-24-hour sleep-wake rhythm disorder in sighted patients. J Clin Sleep Med. 2022;18(2):453-459.

Keywords: circadian rhythm; circadian rhythm sleep disorders; light; melatonin; non–24-hour sleep-wake rhythm disorder.

PubMed Disclaimer

Conflict of interest statement

The final manuscript has been read and approved by all authors. Work for this study was performed at Brigham and Women’s Hospital and Oregon Health & Science University (OHSU). This work was supported by a NARSAD Young Investigator Award to J.S.E., NIH K24-HL105664 to E.B.K. PO1-AG09975 to C.A.C. and E.B.K., NIH MO1-RR02635 to the General Clinical Research Center at Brigham and Women’s Hospital and NIH UL1-RR024140 to the Oregon Clinical and Translational Research Institute at OHSU. None of the funders had any role in this work. Dr. Emens is an expert witness in legal cases, including those involving Teva Pharmaceuticals USA, Inc., Apotex Inc., Apotex Corp., MSN Pharmaceuticals Inc. and MSN Laboratories Pvt. Ltd. Dr. St. Hilaire has provided paid limited consulting for The MathWorks, Inc. Dr. St. Hilaire has received honoraria and travel funds as an invited speaker from the Providence Sleep Research Interest Group and the Mayo Clinic Metabolomics Resource Core. Dr. Klerman has received travel support from the Sleep Research Society, Santa Fe Institute, DGSM (German Sleep Society); Consulting with Puerto Rico Science, Technology and Research Trust, The National Sleep Foundation, Sanofi-Genzyme, and Circadian Therapeutics; partner owns Chronsulting. Dr. Czeisler reports grants to BWH from FAA, NHLBI, NIA, NIOSH, NASA, and DOD; is/was a paid consultant to AARP, American Academy of Dental Sleep Medicine, Eisenhower Medical Center, Emory University, Inselspital Bern, Institute of Digital Media and Child Development, Klarman Family Foundation, M. Davis and Co, Physician's Seal, Sleep Research Society Foundation, State of Washington Board of Pilotage Commissioners, Tencent Holdings Ltd, Teva Pharma Australia, UC San Diego, University of Washington, and Vanda Pharmaceuticals Inc, in which Dr. Czeisler also holds an equity interest; received travel support from Annenberg Center for Health Sciences at Eisenhower, Aspen Brain Institute, Bloomage International Investment Group, Inc., UK Biotechnology and Biological Sciences Research Council, Bouley Botanical, Dr. Stanley Ho Medical Development Foundation, European Biological Rhythms Society, German National Academy of Sciences (Leopoldina), Illuminating Engineering Society, National Safety Council, National Sleep Foundation, Society for Research on Biological Rhythms, Sleep Research Society Foundation, Stanford Medical School Alumni Association, Tencent Holdings Ltd, University of Zurich, and Vanda Pharmaceuticals Inc, Ludwig-Maximilians-Universität München, National Highway Transportation Safety Administration, Office of Naval Research, Salk Institute for Biological Studies/Fondation Ipsen; receives research/education support through BWH from Cephalon, Mary Ann & Stanley Snider via Combined Jewish Philanthropies, Harmony Biosciences LLC, Jazz Pharmaceuticals PLC Inc, Johnson & Johnson, NeuroCare, Inc., Philips Respironics Inc/Philips Homecare Solutions, Regeneron Pharmaceuticals, Regional Home Care, Teva Pharmaceuticals Industries Ltd, Sanofi SA, Optum, ResMed, San Francisco Bar Pilots, Sanofi, Schneider, Simmons, Sysco, Philips, Vanda Pharmaceuticals; is/was an expert witness in legal cases, including those involving Advanced Power Technologies, Aegis Chemical Solutions LLC, Amtrak; Casper Sleep Inc, C&J Energy Services, Catapult Energy Services Group, LLC, Covenant Testing Technologies, LLC, Dallas Police Association, Enterprise Rent-A-Car, Espinal Trucking/Eagle Transport Group LLC/Steel Warehouse Inc, FedEx, Greyhound Lines Inc/Motor Coach Industries/FirstGroup America, Pomerado Hospital/Palomar Health District, PAR Electrical Contractors Inc, Product & Logistics Services LLC/Schlumberger Technology Corp/Gelco Fleet Trust, Puckett Emergency Medical Services LLC, South Carolina Central Railroad Company LLC, Union Pacific Railroad, United Parcel Service/UPS Ground Freight Inc, and Vanda Pharmaceuticals; serves as the incumbent of an endowed professorship provided to Harvard University by Cephalon, Inc.; and receives royalties from McGraw Hill, and Philips Respironics for the Actiwatch-2 and Actiwatch Spectrum devices. Dr. Czeisler’s interests were reviewed and are managed by the Brigham and Women’s Hospital and Mass General Brigham in accordance with their conflict of interest policies. The other authors do not report any conflicts of interest.

Figures

Figure 1
Figure 1. Participant 1.
(A) Double-raster plot of the experimental protocol. Hours are along the horizontal axis and days down the vertical axis; 2 days are plotted across each horizontal line. Sleep timing is represented by the black (self-selected) and gray (scheduled) bars. Hatched bars show the constant routines and yellow bar the timing of the bright light for the melatonin suppression test. Red circles indicate the timing of the dim light melatonin onsets and the green circles are the model simulated time of the onset of melatonin synthesis. The calculated period (denoted by the Greek letter τ) for each segment using different metrics is shown to the right using the same color as in the raster plot (sw: sleep-wake; s: simulation; m: melatonin; t: temperature). Note instances (eg, day 76, orange arrow) where sleep is initiated late relative to the DLMO and might therefore be expected to increase exposure to phase-delaying light and minimize exposure to phase-advancing light. (B) Results of the melatonin suppression test; melatonin levels on the night of the test are represented by the black closed circles and line while melatonin levels from 24-hours prior are represented by the gray line. Light levels are plotted on the secondary y-axis on a log scale; yellow shading plots the timing and intensity of the bright light. (C) Percent wakefulness during forced desynchrony as a function of circadian phase (0° defined as the core body temperature minimum) and time-into-sleep episodes.
Figure 2
Figure 2. Participant 2.
(A) Single-raster plot of wrist actigraphy data from all 332 days of study (black denotes movement); hours are along the horizontal axis and days down the vertical axis. Red circles represent the timing of the salivary dim light melatonin onsets (DLMOs). (B–E) Double-raster plots (black bars denote sleep periods) of sleep diary data from selected days of study and highlight the different sleep-wake patterns observed. In (B) there is a non–24-hour sleep-wake schedule with an overall observed sleep-wake period of 24.7 hours (days 56–96). Note however that there was a week (days 74–81) when the observed sleep-wake period was 32.0 hours (black dashed line). The overall sleep-wake period and observed melatonin periods (red dashed line) were both 24.8 hours from days 73 to 95. (C) is an example of an irregular sleep-wake pattern, (D) shows a predominantly 24-hour sleep-wake pattern, and (E) shows again weeks where the observed sleep-wake period exceeded 30 hours (eg, 35.0 hours, days 210–217 and 39.8 hours, days 228–235).
Figure 3
Figure 3. Participant 3.
Double-raster plot of sleep diary data. Hours are along the horizontal axis and days down the vertical axis; 2 days are shown on each horizontal line. Self-selected sleep timing is represented by the black bars and hatched bars denote missing data. The red circle indicates the timing of the dim light melatonin onset.

Comment in

References

    1. American Academy of Sleep Medicine . International Classification of Sleep Disorders. 3rd ed. Darien, IL: : American Academy of Sleep Medicine; ; 2014. .
    1. Uchiyama M , Lockley SW . Non-24-hour sleep-wake syndrome in sighted and blind patients . Sleep Med Clin. 2009. ; 4 ( 2 ): 195 – 211 . - PubMed
    1. Wever R . The circadian system of man: Results of experiments under temporal isolation. New York, NY: : Springer-Verlag; ; 1979. .
    1. Czeisler CA , Weitzman E , Moore-Ede MC , Zimmerman JC , Knauer RS . Human sleep: its duration and organization depend on its circadian phase . Science. 1980. ; 210 ( 4475 ): 1264 – 1267 . - PubMed
    1. Czeisler CA , Duffy JF , Shanahan TL , et al. . Stability, precision, and near-24-hour period of the human circadian pacemaker . Science. 1999. ; 284 ( 5423 ): 2177 – 2181 . - PubMed

Publication types

MeSH terms